Compare Abeona Therapeutics Inc (ABEO) vs Noble Corporation plc (NE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Noble Corporation plc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Noble Corporation plc trades at $39.57 (market cap $6.12B). The key difference: Noble Corporation plc is far larger — about 16.4× Abeona Therapeutics Inc's market cap, and Noble Corporation plc pays a 5.21% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NE | |
|---|---|---|
Market Cap | $373.32M | $6.12B |
Sector | Health | Technology |
52-Week High | $7.23 | $54.37 |
52-Week Low | $4.17 | $25.70 |
Enterprise Value | $228.22M | $7.37B |
Dividend Yield | — | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Noble Corporation (NE) trades at $37.41, down 1.53% today, with technical indicators showing a bearish trend despite oversold RSI readings. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing in previous quarters. Fundamentals show steady revenue around $3.3 billion with improving net margins to 7.17% in 2026. Noble recently secured a new three-well drilling contract with BP and completed a $800 million senior notes offering to strengthen its financial position.
The stock presents a compelling valuation case with analyst consensus target of $53.33 representing 43% upside potential. However, recent earnings misses and bearish technical signals suggest near-term volatility. The offshore drilling specialist benefits from contract wins and conservative balance sheet management, though execution risks and oil price sensitivity remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
